Form 4: Acrivon Therapeutics Executive Erick Gamelin Reports Stock Transaction
SEC Form 4 Filing
Chief Development Officer Erick Gamelin of Acrivon Therapeutics reports a transaction involving common stock to cover tax obligations.
Summary
- On February 14, 2025, Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, Inc., engaged in a transaction involving the company's common stock.
- The transaction involved the withholding of 469 shares by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- The price per share for the transaction was $5.42.
- Following the transaction, Gamelin directly owns 16,492 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding a stock transaction for tax purposes, indicating a neutral sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it primarily concerns internal tax obligations related to executive compensation.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of stock transaction (tax withholding). |
| 02/19/2025 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.